Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Eun-Suk Kang, Duck Cho, Yong-Man Kim, Kidong Kim, Jae-Weon Kim, Hee Seung Kim, Young-Tae Kim, Jung-Yun Lee, Myong Cheol Lim, Taegwon Oh, Boyeong Song, Insu Jeon, Myunghwan Park, Wu Hyun Kim, Chang-Yuil Kang, Byoung-Gie Kim
BACKGROUND: BVAC-C, a B cell- and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, was well tolerated in HPV-positive recurrent cervical carcinoma patients in a phase I study. This phase IIa study investigates the antitumor activity of BVAC-C in patients with HPV 16- or 18-positive cervical cancer who had experienced recurrence after a platinum-based combination chemotherapy. PATIENTS AND METHODS: Patients were allocated to 3 arms; Arm 1, BVAC-C injection at 0, 4, 8 weeks; Arm 2, BVAC-C injection at 0, 4, 8, 12 weeks; Arm 3, BVAC-C injection at 0, 4, 8, 12 weeks with topotecan at 2, 6, 10, 14 weeks...
2024: Frontiers in Immunology